17 / 28
Page 37
Notes:
allied
academies
J Med Oncl Ther 2017 Volume 2 | Issue 3
International Conference on
Oncology and Cancer Therapeutics
October 30- November 01, 2017 | Chicago, USA
Femtomedicine in cancer: Discovery of new antitumor molecules for natural targeted chemotherapy
and radiotherapy of cancers
Qing-Bin Lu
University of Waterloo, Canada
T
he conquest of cancer continues to pose great challenges
to medical science. There is a compelling need for
innovative cancer research integrating biomedical sciences
with physical sciences in order to ultimately conquer cancer.
Femtomedicine (FMD)
, which integrates femtosecond time-
resolved laser spectroscopy with biomedical sciences, was
recently coined to advance fundamental understanding and
therapies of human diseases notably cancer. Our studies in
FMD have led to the discoveries of the reductive damaging
mechanism in DNA and living cells and the molecular
mechanisms of action of existing anti-cancer agents. These
have offered unique opportunities to develop new effective
drugs for high-performance therapy of cancer. We have
particularly found a new class of non-platinum-based
anticancer compounds (called
FMD compounds
) for natural
targeted chemotherapy and radiotherapy of a variety of
cancers, e.g., cervical cancer, ovarian cancer, head and neck
cancer, breast cancer, lung cancer, etc. Treatments of various
cancer cells
in vitro
and
in vivo
mouse xenograft models
with
FMD compounds
led to effective chemotherapy and
enhanced radiotherapy, while the compounds themselves
induced no or little systemic and radiation toxicity. These
compounds are therefore a new class of potent antitumor
agents that can be translated into clinical trials for targeted
chemotherapy and radiotherapy of multiple types of cancer.
The results also show that FMD can bring breakthroughs in
understanding fundamental biological processes and lead
to advances in cancer therapy. This presentation will discuss
some progress in this new frontier—
FMD in Cancer.
Speaker Biography
Qing-Bin Lu received his PhD from the University of Newcastle, Australia, and completed
his postdoctoral positions at Rutgers University, University of Sherbrooke and
California Institute of Technology. He is a full professor and a University Research Chair
at the University of Waterloo, Canada. His research in
femtomedicine (FMD)
, which
fuses ultrafast laser techniques with biomedical sciences to advance fundamental
understanding and treatment of human diseases, notably cancer, has led to the
discoveries of novel anti-cancer agents for targeted chemotherapy and radiotherapy
of multiple types of cancers. He has published over 50 papers in prestigious journals.
e:
qblu@uwaterloo.ca